Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Planegg, Germany) and analyzed by LC-MS/MS using an EvosepOne nanoLC (Evosep
- Duration: 4-6 weeks
Evidence from Clinical Trials: While dedicated long-term cardiovascular outcome trials (CVOTs) specifically designed to assess the impact of tirzepatide on major adverse cardiovascular events (MACE) are still underway, data from the SURMOUNT and other clinical trial programs provide encouraging signals: SURMOUNT-1 (Obesity without Diabetes): While not a CVOT, this trial showed significant weight loss and improvements in cardiometabolic risk factors in individuals with obesity or overweight without diabetes
When to hold at a current dose If you are still experiencing moderate to severe gastrointestinal side effects at your current dose level, do not escalate
Learn More Advanced 3D body composition analysis at every visit to objectively track your progress over time
